65,437 trials
Paralysis, Legs
Primary: Barriers to Physical Activity Questionnaire for People With Mobility Impairments (BPAQ-MI) — 0.66; 1.24; 0.22; 0.06 units on a scale
Traumatic Brain Injury · Posttraumatic Stress Disorder
Primary: PTSD Symptoms From Baseline as Measured by the Clinician Administered PTSD Scale - 5 — 40.62; 40.53 score on a scale
Birth Asphyxia With Neurologic Involvement
Primary: StO2 in the First 10 Minutes of Life — 70; 74.5 percent
Healthy
Primary: Change in Mindfulness — -0.08; 0.1 score on a scale
Psoriasis
Primary: Percentage of Participants Who Achieve an Intertriginous PGA (iPGA) Score of Clear (0) or Almost Clear (1) With a ≥ 2-grade Improvement — 24 Participants
Chronic Pain
Primary: Percentage Change From Baseline in Overall VAS at 3 Months — -51.3 Percentage change
Type 1 Diabetes
Primary: Time in Range 70-180 mg/dL (TIR) — 11.81 % of time — p=<0.0001
Complex Regional Pain Syndrome (CRPS)
Primary: Rate of Serious Adverse Events (SAEs) — 8.7 percentage of events
Type 1 Diabetes · Pregnancy, High Risk
Primary: Neonatal Hypoglycemia — 49.2; 50.1 mg/dL
Parkinson Disease
Primary: The Percentage of Subjects Who Indicate Preference on Constant Current Over Constant Voltage at the 3 Month Follow-up Visit. — 4 participants
Coronavirus Infection
Primary: Uptake of SARS-CoV-2 Testing as Assessed by Proportion of Participants Who Complete Testing — 199; 205; 218; 78 Participants — p=0.67
Human Papillomavirus Vaccination
Primary: Number of Participants Who Received the Next HPV Vaccine Dose — 51; 27 Participants
Postural Tachycardia Syndrome
Primary: C-peptide Levels After Oral Glucose Tolerance Test — 40.6; 23.2 pg/mL
Opioid Use
Primary: Amount of Pain Experienced — 28; 35 Score on a scale
Alzheimer's Disease
Primary: Computerized Neuropsychological Test Battery (cNTB) Z-Scores - Change From Baseline — 0.0434; 0.1175; 0.0297; 0.0591 z-score